These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34742310)

  • 1. Did the universal zero-markup drug policy lower healthcare expenditures? Evidence from Changde, China.
    Peng Z; Zhan C; Ma X; Yao H; Chen X; Sha X; Coyte PC
    BMC Health Serv Res; 2021 Nov; 21(1):1205. PubMed ID: 34742310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Descriptive Analysis on the Impacts of Universal Zero-Markup Drug Policy on a Chinese Urban Tertiary Hospital.
    Tian W; Yuan J; Yang D; Zhang L
    PLoS One; 2016; 11(9):e0162795. PubMed ID: 27627811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of zero markup drug policy on patients' healthcare utilization and expense: An interrupted time series study.
    Zhu Z; Wang J; Sun Y; Zhang J; Han P; Yang L
    Front Med (Lausanne); 2022; 9():928690. PubMed ID: 36457568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of China's healthcare price reforms on traditional Chinese medicine public hospitals in Beijing: an interrupted time-series study.
    Zhu D; Shi X; Nicholas S; Bai Q; He P
    BMJ Open; 2019 Aug; 9(8):e029646. PubMed ID: 31401602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of China's Public Hospital Reform on Healthcare Expenditures and Utilization: A Case Study in ZJ Province.
    Zhang H; Hu H; Wu C; Yu H; Dong H
    PLoS One; 2015; 10(11):e0143130. PubMed ID: 26588244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study.
    He Y; Dou G; Huang Q; Zhang X; Ye Y; Qian M; Ying X
    PLoS One; 2018; 13(1):e0190320. PubMed ID: 29338038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis.
    Wang J; Li P; Wen J
    BMC Health Serv Res; 2020 Jun; 20(1):519. PubMed ID: 32513170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of healthcare system reforms on public hospitals' revenue structures: Evidence from Beijing, China.
    Gao L; Shi L; Meng Q; Kong X; Guo M; Lu F
    Soc Sci Med; 2021 Aug; 283():114210. PubMed ID: 34274783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The financial impact of the 'zero-markup policy for essential drugs' on patients in county hospitals in western rural China.
    Zhou Z; Su Y; Campbell B; Zhou Z; Gao J; Yu Q; Chen J; Pan Y
    PLoS One; 2015; 10(3):e0121630. PubMed ID: 25790443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different impacts of the zero-markup drug policy on county general and traditional Chinese medicine hospitals: evidence from Shandong province, China.
    Jiang X; He P; Zhu D; Shi X; Meng Q
    Int J Equity Health; 2020 Dec; 19(1):219. PubMed ID: 33302978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Chinese medical pricing reform on the structure of hospital revenue and healthcare expenditure in county hospital: an interrupted time series analysis.
    Liu M; Jia M; Lin Q; Zhu J; Wang D
    BMC Health Serv Res; 2021 Apr; 21(1):385. PubMed ID: 33902578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the National Essential Medicines Policy on health expenditures and service delivery in Chinese township health centres: evidence from a longitudinal study.
    Zhang X; Wu Q; Liu G; Li Y; Gao L; Guo B; Fu W; Hao Y; Cui Y; Huang W; Coyte PC
    BMJ Open; 2014 Dec; 4(12):e006471. PubMed ID: 25534214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the zero-mark-up drug policy on drug-related expenditures and use in public hospitals, 2016-2018: an interrupted time series study in Shaanxi.
    Yan K; Yang C; Zhang H; Ye D; Liu S; Chang J; Jiang M; Zhao M; Fang Y
    BMJ Open; 2020 Nov; 10(11):e037034. PubMed ID: 33243788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the separating of hospital revenue from drug sales reduce the burden on patients? Evidence from China.
    Li L; Yu Q
    Int J Equity Health; 2021 Jan; 20(1):12. PubMed ID: 33407503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unbalanced Treatment Costs of Breast Cancer in China: Implications From the Direct Costs of Inpatient and Outpatient Care in Liaoning Province.
    Ma Z; Deng G; Meng Z; Ma Y; Wu H
    Int J Health Policy Manag; 2022 Sep; 11(9):1735-1743. PubMed ID: 34380200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the performance of social health insurance system through increasing outpatient expenditure reimbursement ratio: a quasi-experimental evaluation study from rural China.
    Miao Y; Gu J; Zhang L; He R; Sandeep S; Wu J
    Int J Equity Health; 2018 Jun; 17(1):89. PubMed ID: 29940956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intended and unintended impacts of price changes for drugs and medical services: Evidence from China.
    Fu H; Li L; Yip W
    Soc Sci Med; 2018 Aug; 211():114-122. PubMed ID: 29935401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of public hospital pricing reform on medical expenditure structure in Jiangsu, China: a synthetic control analysis.
    Zang X; Zhang M; Wei S; Tang W; Jiang S
    BMC Health Serv Res; 2019 Jul; 19(1):512. PubMed ID: 31337396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term and long-term unintended impacts of a pilot reform on Beijing's zero markup drug policy: a propensity score-matched study.
    Zeng J; Chen X; Fu H; Lu M; Jian W
    BMC Health Serv Res; 2019 Nov; 19(1):916. PubMed ID: 31783751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Trend in medical expenditures for patients with kidney diseases: An analysis from a tertiary hospital in Beijing].
    Bi SH; Li ZF; Wang T; Wang Y; Zhang C; Ji H; Shi J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Nov; 53(1):215-219. PubMed ID: 33550360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.